To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
Clinical trial NCT00120328 · TERMINATED
Trial details
- NCT number
- NCT00120328
- Sponsor
- Speedel Pharma Ltd.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2005-07-01
- Enrollment
- 2364
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.